Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs AT&T Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while AT&T Inc. trades at $24.49 (market cap $164.80B). The key difference: AT&T Inc. is far larger — about 32.6× ACADIA Pharmaceuticals Inc.'s market cap, and AT&T Inc. pays a 4.62% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | T | |
|---|---|---|
Market Cap | $5.06B | $164.80B |
Sector | Health | Media |
52-Week High | $29.41 | $29.62 |
52-Week Low | $20.06 | $20.49 |
Enterprise Value | $4.18B | $310.12B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
AT&T (T) trades at $23.80, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.65 exceeding the $0.59 estimate. Revenue grew to $125.65 billion in 2025, and net income surged to $21.95 billion, reflecting a robust profit margin of 17.47%. Recent news highlights fiber expansion and 5G network investments.
The outlook is positive, supported by improving cash flow, strategic investments, and a 4.8% dividend yield. However, risks include competitive pressure from new entrants like SpaceX's Starlink and high debt levels. Analyst sentiment is mixed but leans bullish, with 41% buy ratings. The stock presents a value opportunity with a low P/E of 7.85, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
